BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b) (c) On June 5, 2019, Bristol-Myers Squibb Company (the “Company”) announced the future leadership team of the combined company effective upon completion (the “Closing”) of the Company’s pending merger with Celgene Corporation (“Celgene”). Among the changes announced are the following appointment and departure of certain officers:

Mr. Elkins is 50 years old and joined Celgene in July 2018 and was appointed Chief Financial Officer in August 2018. He came to Celgene from Johnson & Johnson (“J&J”), where he was Group Vice President and Chief Financial Officer for Consumer Products, Medical Devices and Corporate Functions. Prior to J&J, Mr. Elkins was CFO for Round Rock Research, a technology investigation and patent licensing company. From 2008 to 2012, Mr. Elkins was Executive Vice President and CFO of Becton, Dickinson and Company, a public global medical technology company. From 1995 to 2008, he held roles of increasing responsibility at AstraZeneca, and he began his career in finance at the Boeing Company in 1991. Mr. Elkins holds a B.S. degree from the University of Delaware, an M.S. from the University of Pennsylvania and an M.B.A. from Drexel University.

There are no arrangements or understandings between Mr. Elkins and any other persons to which he was selected as Chief Financial Officer. There are no related party transactions between the Company and Mr. Elkins and there are no family relationships between Mr. Elkins and any director or executive officer of the Company.

(e) In connection with his departure, Dr. Lynch will be entitled to severance benefits in accordance with the Company’s Senior Executive Severance Plan, a prorated annual incentive payout in accordance with the Company’s Senior Executive Performance Incentive Plan and pro-rated vesting of equity awards in accordance with the Company’s equity award agreements under the Company’s 2012 Stock Award and Incentive Plan. In addition, upon his departure, the Company will enter into a consulting agreement with Dr. Lynch for twelve months for which he will receive $83,333 per month.

In connection with his appointment as Executive Vice President and Chief Financial Officer, Mr. Elkins will receive the following compensation effective as of the Closing:

In addition, Mr. Elkins will receive a cash sign-on payment of $2,100,000, to be paid 50% as soon as practicable following the Closing, 25% on the one-year anniversary of the Closing and 25% on the two-year anniversary of the Closing, and a Restricted Stock Unit award valued at $2,000,000 that will vest at the rate of 25% on each of the first, second, third and fourth anniversaries of the grant date.

A copy of the press release announcing the leadership team changes effective upon the Closing is attached to this report as Exhibit 99.1.

The transaction remains subject to regulatory approvals and other customary closing conditions.

Important Information For Investors And Stockholders

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

Statement on Cautionary Factors

This Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can identify these forward-looking statements by the fact that they use words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and others words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. You can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements are likely to relate to, among other things, statements about the consummation of the Merger and projections as to the anticipated benefits thereof and current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations.

Important risk factors could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to, the risks that: the completion of the Merger may not occur on the anticipated terms and timing or at all; a condition to the closing of the Merger may not be satisfied; the combined company will have substantial indebtedness following the completion of the Merger; Bristol-Myers Squibb is unable to achieve the synergies and value creation contemplated by the Merger; Bristol-Myers Squibb is unable to promptly and effectively integrate Celgene’s businesses; management’s time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company decline following the Merger; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company; Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel; and the announcement or the consummation of the Merger has a negative effect on the market price of the capital stock of Bristol-Myers Squibb and Celgene or on Bristol-Myers Squibb’s and Celgene’s operating results.

Additional information concerning these risks, uncertainties and assumptions can be found in Bristol-Myers Squibb’s and Celgene’s respective filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in Bristol-Myers Squibb’s and Celgene’s most recent Annual Reports on Form 10-K, as updated by their Quarterly Reports on Form 10-Q and future filings with the SEC. Except as otherwise required by law, Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are included as part of this Current Report on Form 8-K:

EXHIBIT INDEX

BRISTOL MYERS SQUIBB CO Exhibit
EX-99.1 2 nc10002432x1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Bristol-Myers Squibb Announces Post-Closing Leadership Team • Experienced leadership team and evolved structure position company to drive in-line business,…
To view the full exhibit click here

About BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP)

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.